biotech

biotech Articles

CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration with Vertex Pharmaceuticals.
Ionis Pharmaceuticals shares were relatively flat on Wednesday after the company announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.
The September 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Mylan shares hit a 52-week low after Mapi Pharma announced midstage results from its multiple sclerosis trial.
Affimed shares took a big step back early on Tuesday after the company announced that it has placed its AFM11 on clinical hold, and has notified the global health authorities of its decision.
Biopharmaceutical company Orchard RX Limited has filed with the SEC for its initial public offering.
Akcea Therapeutics shares pulled back on Monday after the company announced a big change to its board of directors.
Exelixis shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
Vaxart shares more than doubled on Thursday after the company announced positive results from the midstage trial of its influenza oral tablet vaccine.
Arrowhead Pharmaceuticals shares stumbled on Thursday after it announced a license and collaboration agreement with Janssen Pharmaceutica, a subsidiary of Johnson & Johnson.
Synthetic biology company Twist Bioscience has filed with the SEC regarding its initial public offering.
Clovis Oncology shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.
Akorn shares were crushed early on Monday after a Delaware judge ruled that German health care group Fresenius could walk away from its $4.75 billion merger deal.
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.